PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection

Condition(s) studied

Investigational drug(s) / intervention(s)

Ceftazidime Avitbatan Sodium: For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.

Study summary

Ceftazidime avitbatan sodium is a broad-spectrum antibiotic with an antimicrobial spectrum covering resistant gram-negative bacteria. Its use in pediatric intensive care for severe infections is not unusual. Pathophysiological changes in severe sepsis can lead to significant changes in pharmacokinetics and pharmacodynamics during continuous renal replacement therapy.This research aims to study change of pharmacokinetic and pharmacodynamic in severe infection children with extracorporeal life support, thus improve the treatment of severe sepsis and sepsis shock.

Eligibility

Primary outcome measure(s)

• Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter — Day 1-5
  Time to reach the maximum plasma concentration (Tmax) after administrations of a single dose and multiple doses of the study drug

Trial sites (1)

More Children's Hospital of Fudan University trials in China

Other trials for the same condition